Corvus Pharmaceuticals CRVS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's total liabilities & equity?
- Corvus Pharmaceuticals (CRVS) reported total liabilities & equity of $253.2M in Q1 2026.
- How has Corvus Pharmaceuticals's total liabilities & equity changed year-over-year?
- Corvus Pharmaceuticals's total liabilities & equity increased by 326.0% year-over-year, from $59.44M to $253.2M.
- What is the long-term trend for Corvus Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total liabilities & equity has grown at a -3.6% compound annual growth rate (CAGR), from $85.53M to $71.12M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.